USPTO Updates Guidance On Enablement

In 2023, the U.S. Supreme Court affirmed invalidity of two Amgen patents based on a lack of enablement for broad genus claims that would potentially encompass millions of antibodies. The Court1...

Related Keywords

Justice Gorsuch ,Proprotein Convertase Subtilisin Kexin ,Baxalta Incorporated ,Supreme Court ,Us Supreme Court ,Medytox Inc ,Amgen Inc ,Amgen ,Genetech Inc ,Trademark Office ,Patent Statute ,Federal Circuit ,Wands Factors ,Markets ,